Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung.

Kazemi-Bajestani SMR, Becher H, Butts C, Basappa NS, Smylie M, Joy AA, Sangha R, Gallivan A, Kavsak P, Chu Q, Baracos VE.

J Cachexia Sarcopenia Muscle. 2019 Jul 10. doi: 10.1002/jcsm.12451. [Epub ahead of print]

2.

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.

Ni D, AlZahrani F, Smylie M.

Case Rep Oncol. 2019 Jun 19;12(2):456-465. doi: 10.1159/000500856. eCollection 2019 May-Aug.

3.

Disorder raises the critical temperature of a cuprate superconductor.

Leroux M, Mishra V, Ruff JPC, Claus H, Smylie MP, Opagiste C, Rodière P, Kayani A, Gu GD, Tranquada JM, Kwok WK, Islam Z, Welp U.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):10691-10697. doi: 10.1073/pnas.1817134116. Epub 2019 May 13.

PMID:
31085657
4.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.

J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.

5.

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.

Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M, Lyddell C, Ye C.

Clin Rheumatol. 2019 May;38(5):1513-1519. doi: 10.1007/s10067-019-04451-2. Epub 2019 Jan 30.

PMID:
30701346
6.

Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.

Joseph K, Alkaabi K, Warkentin H, Ghosh S, Jha N, Smylie M, Walker J.

J Med Imaging Radiat Oncol. 2019 Apr;63(2):257-263. doi: 10.1111/1754-9485.12842. Epub 2018 Dec 14.

PMID:
30549229
7.

Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials.

Kazemi-Bajestani SMR, Becher H, Butts C, Basappa NS, Smylie M, Joy AA, Sangha R, Gallivan A, Chu Q, Baracos VE.

Support Care Cancer. 2019 Apr;27(4):1551-1561. doi: 10.1007/s00520-018-4561-y. Epub 2018 Dec 13.

PMID:
30547303
8.

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.

Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S.

Curr Oncol. 2018 Oct;25(5):e373-e384. doi: 10.3747/co.25.3840. Epub 2018 Oct 31.

9.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.

Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30361170
10.

Hepatitis is the new myositis: immune checkpoint inhibitor-induced myositis.

Roberts JH, Smylie M, Oswald A, Cusnir I, Ye C.

Melanoma Res. 2018 Oct;28(5):484-485. doi: 10.1097/CMR.0000000000000485. No abstract available.

PMID:
30148768
11.

Sexual and somatic development of wood frog tadpoles along a thermal gradient.

Lambert MR, Smylie MS, Roman AJ, Freidenburg LK, Skelly DK.

J Exp Zool A Ecol Integr Physiol. 2018 Feb;329(2):72-79. doi: 10.1002/jez.2172. Epub 2018 May 23.

PMID:
29791087
12.

Superconducting and normal-state anisotropy of the doped topological insulator Sr0.1Bi2Se3.

Smylie MP, Willa K, Claus H, Koshelev AE, Song KW, Kwok WK, Islam Z, Gu GD, Schneeloch JA, Zhong RD, Welp U.

Sci Rep. 2018 May 16;8(1):7666. doi: 10.1038/s41598-018-26032-0.

13.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

14.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.

15.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
16.

Health-related quality of life results from the phase III CheckMate 067 study.

Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV.

Eur J Cancer. 2017 Sep;82:80-91. doi: 10.1016/j.ejca.2017.05.031. Epub 2017 Jun 23.

17.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M.

Lancet Oncol. 2017 May;18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27.

PMID:
28359784
18.

Sun-Smart Practices Amongst School Students (Grades 5, 7, and 9) in Alberta, Canada.

Jha D, Jha S, Ghosh S, Smylie M, Taher M.

J Cutan Med Surg. 2017 Mar/Apr;21(2):137-144. doi: 10.1177/1203475417692574.

PMID:
28300452
19.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AMM.

Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.

20.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

Supplemental Content

Loading ...
Support Center